Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

The rise of part-time C-suite roles in biotech offers a hidden advantage by cross-pollinating experience between startups. However, this model risks diluting the intense, "back-to-the-wall" ownership and singular mission focus that is crucial for a new company's success, creating a have/have-not divide.

Related Insights

Ben Horowitz advises against the traditional CEO/COO 'Mr. Outside/Mr. Inside' structure in small companies. He argues it creates a flawed communication architecture, akin to having two people in charge, which hinders agility. A flatter structure is generally better for an early-stage tech company.

CEO Marc Salzberg wears CEO, CMO, and Board Chair hats, acknowledging it's a temporary "big stretch." This demonstrates a practical early-stage strategy where a leader covers multiple critical functions to save capital and ensure continuity, with a clear plan to hire dedicated experts as the company matures.

To prevent losing top scientific talent to administrative roles, the "Venture Catalyst" model pairs a scientist-founder with a dedicated business team. This allows the scientist to remain in the lab, focused on research, while the experienced partners handle finance, legal, and daily management.

To maintain a collaborative, "no lanes" culture while scaling, Coya's CEO prioritizes hiring individuals with a strong sense of curiosity and a willingness to learn. This strategy counteracts the silo-building tendency of hiring narrow experts who may be less adaptable or open to cross-functional input.

Beyond simple headcount growth, a biotech's culture must fundamentally shift as it matures. Moving into clinical trials requires a new focus on patient safety and regulation, while commercialization introduces intense pressure for compliance and revenue generation.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

The old model of replacing a founder with a 'professional CEO' is often flawed because it removes irreplaceable product insight. The modern approach is for founders to design their executive team to complement their unique strengths, ensuring they stay engaged for the long journey.

Founders transitioning from the lab to a CEO role often misjudge the immense time commitment required for leadership. Building a cohesive team culture, especially across multiple locations, demands significant, active effort, including prioritizing in-person meetings to establish trust and shared values.

Highly empathetic, guilt-prone individuals often avoid top leadership roles due to the immense pressure and responsibility. Redesigning these positions to be shared (e.g., co-CEOs) diffuses this burden, making leadership more attractive to those who care most about others.

A CEO without a deep scientific background can thrive in biotech by acting as a synthesizer. The key is not to blindly delegate to experts, but to ask probing questions, understand the interplay between disciplines (regulatory, clinical, etc.), and connect them for effective decision-making.